Literature DB >> 6470190

Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.

A Shvartsburd, C Sajadi, V Morton, M Mirabi, J Gordon, R C Smith.   

Abstract

Plasma and red blood cell levels of haloperidol, thioridazine, and thioridazine's main metabolite mesoridazine were measured in schizophrenic outpatients during treatment with fixed doses of haloperidol or thioridazine for several months. These drug levels were compared to those in schizophrenic inpatients treated with fixed doses of the same neuroleptics. There were large interpatient variations in plasma and red blood cell levels at a given dose for schizophrenic outpatients as well as for inpatients. The intrapatient day-to-day fluctuation was much greater in the outpatients. The mean coefficient of variation of thioridazine or mesoridazine levels was about two-fold higher in schizophrenic outpatients than in inpatients. Differences in blood sampling time or compliance in medication ingestion do not fully explain the issue. The factors accounting for the increased intrapatient variability of plasma levels of thioridazine, mesoridazine, and haloperidol in schizophrenic outpatients remain unclear.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470190

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  4 in total

Review 1.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

Review 2.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

3.  Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.

Authors:  M L Rao; W A Brown
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Thioridazine for schizophrenia.

Authors:  M Fenton; J Rathbone; J Reilly; A Sultana
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.